Marea Therapeutics

Marea Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for cardiometabolic diseases. Their approach leverages large-scale human genetic data and a deep understanding of adipocyte biology to target critical and unaddressed drivers of these diseases. Marea's lead program, MAR001, is a monoclonal antibody targeting ANGPTL4, a protein highly expressed in adipose tissue. By inhibiting ANGPTL4, MAR001 aims to lower remnant cholesterol and improve adipose tissue function, offering potential benefits for patients with metabolic dysfunction.

Marea is led by a renowned team of scientists, clinical advisors, and biopharma executives with extensive experience in human genetics, adipocyte biology, and cardiometabolic disease drug development. They are committed to developing therapies that complement existing treatment options and serve as transformative solutions for patients struggling with cardiometabolic diseases, particularly those with elevated remnant cholesterol levels.

Marea Therapeutics is a fast-growing company with a strong emphasis on innovation in the field of cardiometabolic diseases. Their website focuses on their science, pipeline, team, news, and careers. The information provided about their workplace culture and job flexibility is limited.

Marea Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for cardiometabolic diseases. Leveraging advanced human genetics and a deep understanding of adipocyte biology, Marea aims to address the underlying causes of these conditions, targeting critical and unaddressed drivers like remnant cholesterol, a key contributor to heart disease risk. Their therapies, like MAR001, a monoclonal antibody targeting ANGPTL4, have the potential to complement existing treatments and offer transformative options for the millions of patients living with cardiometabolic diseases.

Marea Therapeutics promotes a culture of innovation and collaboration, driven by a shared passion for developing groundbreaking treatments for cardiometabolic diseases. The company values a diverse and inclusive team, attracting individuals with expertise in human genetics, adipocyte biology, and drug development. Their leadership team, comprised of renowned scientists and biopharma executives, fosters a supportive and challenging environment that encourages creativity and scientific exploration.